This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ketas, T. J.
Right arrow Articles by Pope, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ketas, T. J.
Right arrow Articles by Pope, M.

 Previous Article  |  Next Article 

Journal of Virology, February 2003, p. 2762-2767, Vol. 77, No. 4
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.4.2762-2767.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active against both Direct and trans Infection of Primary Cells

Thomas J. Ketas,1 Ines Frank,2 Per Johan Klasse,3 Brian M. Sullivan,1 Jason P. Gardner,1 Catherine Spenlehauer,4 Mirjana Nesin,5 William C. Olson,1 John P. Moore,4 and Melissa Pope2*

Progenics Pharmaceuticals, Inc., Tarrytown, New York 10591,1 Department of Microbiology and Immunology,4 Department of Pediatrics, Weill Medical College of Cornell University,5 Center for Biomedical Research, Population Council, New York, New York 10021,2 Jefferiss Research Trust Laboratories, Wright-Fleming Institute, Imperial College, London W2 1PG, United Kingdom3

Received 21 August 2002/ Accepted 18 November 2002


arrow
ABSTRACT
 
Inhibitors of human immunodeficiency virus type 1 attachment (CD4-immunoglobulin G subclass 2), CCR5 usage (PRO 140), and fusion (T-20) were tested on diverse primary cell types that represent the major targets both for infection in vivo and for the inhibition of trans infection of target cells by virus bound to dendritic cells. Although minor cell-type-dependent differences in potency were observed, each inhibitor was active on each cell type and trans infection was similarly vulnerable to inhibition at each stage of the fusion cascade.


arrow
TEXT
 
Human immunodeficiency virus type 1 (HIV-1) entry proceeds via the sequential steps of gp120-CD4 attachment, gp120-coreceptor interactions, and gp41-mediated fusion (9, 21). CD4-immunoglobulin G subclass 2 (CD4-IgG2) (PRO 542) is an HIV-1 attachment inhibitor that has shown promise in phase I/II testing (18, 26, 31). PRO 140 (PA14) is an anti-CCR5 monoclonal antibody (27, 37) that is entering phase I testing. The fusion inhibitor T-20 is a peptide derived from HIV-1 gp41; it targets a transient gp41 conformation formed after coreceptor binding (5). T-20 has demonstrated promising safety and antiviral effects in phase III testing (B. Clotet, A. Lazzarin, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, J. Chung, L. Fang, J. Delehanty, and M. Salgo, 14th Int. AIDS Conf., abstr. LbOr19A, 2002; K. Henry, J. Lalezari, M. O'Hearn, B. Trottier, J. Montaner, P. Piliero, S. Walmsley, J. Chung, L. Fang, J. Delehanty, and M. Salgo, 14th Int. AIDS Conf., abstr. LbOr19B, 2002).

Studies of entry inhibitors typically have utilized cultured cell lines or peripheral blood mononuclear cells (PBMC). However, HIV-1 replicates in additional cell types and tissues in vivo (4, 12, 33, 40) and these have important implications for therapy.

Entry inhibitors could also be used prophylactically. Dendritic cells (DC) at surface epithelia may disseminate virus to susceptible cells in draining lymphoid tissue (16, 35). Cord blood mononuclear cells (CBMC) provide an available source of cells relevant to vertical transmission.

Whereas immature DC replicate HIV-1 efficiently, mature DC are poorly infectible (14). However, mature DC can bind virus and mediate the infection of cocultured CD4+ T cells in trans. There are conflicting reports on the susceptibility of cell-bound virus to neutralizing antibodies (13, 15, 34), and other classes of entry inhibitors have not been similarly studied. Here, we explore the breadth of activity in vitro of the three main classes of HIV-1 entry inhibitors.

Direct infection of diverse primary cell types. We first tested the inhibitors for activity on diverse primary cells. CD4-IgG2, murine PRO 140, and T-20 were prepared as described previously (1, 24, 37). RANTES (PeproTech, Rocky Hill, N.J.), a natural chemokine ligand for CCR5, was tested for comparison. The studies examined the subtype B CCR5-using (R5) primary isolates HIV-1JR-FL (25), HIV-1SF162 (7), and HIV-1Case C 1/85 (8).

PBMC and CBMC (36), macrophages (37), and mature and immature DC (11) were isolated and cultured according to published methods. The inhibition assay was performed essentially as described previously (38). Briefly, inhibitors were combined for 1 h at 37°C with virus (CD4-IgG2 and T-20) or target cells (PRO 140 and RANTES). Inhibitors, virus, and cells were then incubated for 5 to 7 days at 37°C, and the extent of viral replication was determined by p24 antigen enzyme-linked immunosorbent assay of the culture supernatants. The viral inocula in 50% tissue culture infective doses were 400 to 1,000 for PBMC and CBMC, 1,000 for macrophages, and 5,000 to 10,000 for DC.

Table 1 summarizes the concentrations required for 90% (IC90) and 50% (IC50) inhibition for the various cell types. The median IC90s for CD4-IgG2, PRO 140, RANTES, and T-20 in PBMC cultures were 13, 31, 16, and 62 nM, respectively (Table 1). These values are consistent with those from prior studies of these agents (24, 37-39).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Interisolate variation in inhibitor activity for direct and trans infection of primary cells

CD4-IgG2, PRO 140, and T-20 each mediated 90% inhibition of viral replication in PBMC, CBMC, macrophages, and immature DC (Table 1). In contrast, RANTES was ineffective in macrophage cultures, as reported previously (2, 3, 10, 28-30, 32, 37). Although RANTES blocked virus replication by 50% at moderate concentrations (Table 1), higher concentrations often led to the enhancement of infection (data not shown). Inhibition studies were not conducted on mature DC, which were poorly susceptible to infection.

For comparison of cell type differences in inhibitor potency, we used log-transformed IC50s and IC90s, which more closely followed a Gaussian distribution than did the raw values, facilitating comparison of the means by two-tailed t tests. ICs observed for PBMC were compared with those for other cell types. Since the t test was performed four times for each drug, the threshold P value was adjusted from 0.05 to 0.013 in accordance with Bonferroni's correction.

For a given inhibitor, the mean ICs for the other cell types tended to cluster about the values observed for PBMC (Fig. 1). Thus CD4-IgG2, PRO 140, and T-20 are broadly active in blocking the entry of HIV-1 into PBMC, CBMC, macrophages, and immature DC. These findings are consistent with those of a similarly designed study employing RANTES, T-20, and the CCR5 antagonist SCH-C (19a).






View larger version (70K):
[in this window]
[in a new window]
  		FIG. 1. Cell-type-specific variations in inhibitor activity. IC50s and IC90s were observed for CD4-IgG2 (A), PRO 140 (B), T-20 (C), and RANTES (D) against HIV-1JR-FL (open circles), HIV-1SF162 (filled squares), and HIV-1Case C 1/85 (filled triangles) on the indicated cell types. Overall mean log IC50s and IC90s for all assays are indicated with horizontal bars. Mean log ICs that differed significantly (P < 0.013) from the corresponding value for PBMC are indicated with an asterisk. (A) CD4-IgG2. The mean log IC90s and IC50s obtained for macrophages were significantly lower than those obtained for PBMC (P = 7.9 x 10-7 for both IC90 and IC50). Mean log ICs for CBMC were also lower than those for PBMC (P = 0.0039 and 0.0045 for IC90 and IC50, respectively). None of the other values were significantly different from those for PBMC. (For IC90s, P = 0.96 for immature DC and 0.78 for DC in trans. For IC50s, P = 0.91 for immature DC and 0.82 for DC in trans.) (B) PRO 140. The mean log IC90 for immature DC was significantly higher than that for PBMC (P = 5.7 x 10-4). None of the other mean log IC90s were different from those for PBMC (P = 0.63 for macrophages, 0.19 for CBMC, and 0.38 for DC in trans). None of the IC50s differed from that for PBMC (P = 0.33 for immature DC, 0.23 for macrophages, 0.94 for CBMC, and 0.89 for DC in trans). (C) T-20. Immature DC had an IC90 higher than that for PBMC (P = 8.8 x 10-4). No other cell types had IC90s different from those for PBMC (P = 0.47 for macrophages, 0.62 for CBMC, and 0.19 for DC in trans). No IC50s were different compared to those for PBMC (P = 0.17 for immature DC, 0.34 for macrophages, 0.32 for CBMC, and 0.76 for DC in trans). (D) RANTES. Macrophages had higher mean log ICs than did PBMC (P = 4.8 x 10-7 for IC90 and 2.9 x 10-4 for IC50). The IC90s for immature DC bordered on being significantly higher than those for PBMC (P = 0.013). No other cell types had ICs different from those for PBMC. (For IC90s, P = 0.43 for CBMC and 0.63 for DC in trans. For IC50s, P = 0.31 for immature DC, 0.96 for CBMC, and 0.21 for DC in trans.) Any higher ICs for immature DC may reflect the 10-fold greater virus doses used to detect production infection in these assays.

Although the entry inhibitors were broadly active, cell type differences in potency were observed. CD4-IgG2 was ninefold (P = 7.9 x 10-7) and sixfold (P = 0.0039) more potent when assayed on macrophages and CBMC, respectively, than on PBMC. Notably, macrophages and CBMC express comparatively low levels of CD4 (6, 23). Immature DC required higher ICs, with the mean IC90s of T-20 and PRO 140 being ninefold (P = 8.8 x 10-4) and sixfold (P = 5.7 x 10-4) higher than their respective PBMC values. These findings may reflect the higher concentration of virus inoculum required to infect immature DC.

Correlation between the potencies of entry inhibitors. We next performed linear regression analysis of the log IC90s observed for a pair of inhibitors within a given experiment, keeping the virus, cell type, and cell donor constant. Data obtained with different cell types were pooled to increase the statistical power. An r2 of >0.25 was deemed indicative of a strong correlation, and in those cases, P values were calculated by using JMP software (SAS Institute, Inc., Cary, N.C.).

Significant correlations were observed in the cases of PRO 140 and RANTES (r2 = 0.26, P = 0.0005) and PRO 140 and T-20 (r2 = 0.34, P < 0.0001). Both correlations were positive; i.e., a virus culture that was sensitive to one inhibitor was sensitive to the other. The correlation observed for PRO 140 and RANTES is perhaps unsurprising, given both are CCR5 inhibitors. The correlation between PRO 140 and T-20 may reflect the fact that these agents act at sequential, interdependent stages of fusion.

CD4-IgG2's potency did not correlate with that of any other inhibitor and thus may be influenced by an independent set of viral and host determinants. Distinct resistance determinants are desirable for therapy.

Regression analysis was used to examine other potential correlates of activity. However, for a given cell type and inhibitor, no significant correlation could be established based on the virus isolate, cell donor, or degree of viral replication or "fitness." These variables may have complex combinatorial effects on inhibition, and further studies are needed to dissect the relative contributions.

DC-mediated infection in trans. We next examined the inhibition of trans infection. Briefly, CD14+ and CD14- cells were isolated as described previously (11, 36). The CD14- cells were cryopreserved, while the CD14+ cells were differentiated into mature DC (11). DC were incubated overnight at 37°C with 10,000 tissue culture infective doses/ml of virus, washed five times, resuspended in PBMC culture medium (36), seeded at 2 x 105 cells/well in 96-well plates, and incubated with CD4-IgG2 or T-20 for 1 h at 37°C. CD14- cells were thawed, stimulated as described previously (36), and incubated with PRO 140 or RANTES. CD14- cells (1.4 x 105 cells/well) were then added to DC, and HIV-1 replication was determined as described above.

Each inhibitor effectively blocked trans infection. In no case did the ICs for a given inhibitor vary by more than threefold between direct and trans infection of PBMC (Table 1 and Fig. 1). Thus, during trans infection, DC-associated virus is sensitive to inhibition throughout the fusion cascade.

Thus DC-mediated trans infection is inhibited by CD4-IgG2 as well as HIV-1-neutralizing monoclonal antibodies (13, 17). In contrast, follicular DC-mediated trans infection reportedly is unaffected by neutralizing antibody (15). The divergent results could reflect differences both in how DC versus follicular DC process immune-complexed virus and in assay methodology.

Similarly, we observed that T-20 efficiently blocks DC-mediated trans infection. Our findings stand in apparent contrast to those reported for trans infection mediated by intestinal epithelial cells, where T-20 was inactive (22). However, the different outcomes may again reflect methodology differences. In the earlier study, T-20 was removed from the epithelial cells prior to the addition of CD4+ target cells (22), whereas T-20 was present in our DC-T-cell cocultures.

In the present study, DC were added in excess of T cells such that most of the T cells could be infected in trans during the first round of infection. To explore the potential importance of secondary rounds of infection, inhibitors were washed away prior to the combination of DC and T cells. CD4-IgG2 was fully active in the washout setting (data not shown), indicating that the agent blocks trans infection. These findings support the notion that the inhibitors block trans infection.

Our findings shed light on the mechanism of HIV-1 infection in trans. Notably, during this process, virus is sensitive to each of the known classes of entry inhibitors. This result is surprising for two reasons. Firstly, lentiviruses are internalized in prominent vacuoles in mature DC (11) and internalization may be critical for infection (20). Secondly, trans infection may occur at polarized interfaces between the cells (19) and internalized virus moves to this immunologic synapse within minutes of cell contact (D. McDonald, D. Unatmaz, V. KewalRamani, and T. Hope, Keystone Symp. HIV Pathog., abstr. 121, 2002). Nonetheless, our findings indicate that virus remains vulnerable to inhibition by membrane-impermeable drugs.

In summary, we report that the main classes of HIV-1 entry inhibitors block the direct and trans infection of multiple primary cell types. Although minor cell-type-specific differences in activity were observed, CD4-IgG2, PRO 140, and T-20 were effective in each setting. Our findings also offer new insights into the nature of the DC/T-cell synapse during trans infection.


arrow
ACKNOWLEDGMENTS
 
M.P. is an Elizabeth Glaser Scientist of the Pediatric AIDS Foundation. J.P.M. is a Stavros S. Niarchos Scholar.

This work was funded by NIH grants AI46871, R01 AI43084, R01 AI40877, R01 AI41420, and P01 AI52048; The Rockefeller Foundation; the Elizabeth Glaser Pediatric AIDS Foundation; and Progenics Pharmaceuticals, Inc. The Department of Microbiology and Immunology at the Weill Medical College gratefully acknowledges the support of the William Randolph Hearst Foundation.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Center for Biomedical Research, Population Council, 1230 York Ave., New York, NY 10021. Phone: (212) 327-7794. Fax: (212) 327-7764. E-mail: mpope{at}popcbr.rockefeller.edu. Back


arrow
REFERENCES
 
    1
  1. Allaway, G. P., K. L. Davis-Bruno, G. A. Beaudry, E. B. Garcia, E. L. Wong, A. M. Ryder, K. W. Hasel, M.-C. Gauduin, R. A. Koup, J. S. McDougal, and P. J. Maddon. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retrovir. 11:533-539.[Medline]
    2. 2
  2. Amzazi, S., L. Ylisastigui, Y. Bakri, L. Rabehi, L. Gattegno, M. Parmentier, J. C. Gluckman, and A. Benjouad. 1998. The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state. Virology 252:96-105.[CrossRef][Medline]
    3. 3
  3. Arenzana-Seisdedos, F., J. L. Virelizier, D. Rousset, I. Clark-Lewis, P. Loetscher, B. Moser, and M. Baggiolini. 1996. HIV blocked by chemokine antagonist. Nature 383:400.[CrossRef][Medline]
    4. 4
  4. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.[CrossRef][Medline]
    5. 5
  5. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.[CrossRef][Medline]
    6. 6
  6. Collman, R., B. Godfrey, J. Cutilli, A. Rhodes, N. F. Hassan, R. Sweet, S. D. Douglas, H. Friedman, N. Nathanson, and F. Gonzalez-Scarano. 1990. Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor. J. Virol. 64:4468-4476.[Abstract/Free Full Text]
    7. 7
  7. Collman, R., N. F. Hassan, R. Walker, B. Godfrey, J. Cutilli, J. C. Hastings, H. Friedman, S. D. Douglas, and N. Nathanson. 1989. Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J. Exp. Med. 170:1149-1163.[Abstract/Free Full Text]
    8. 8
  8. Connor, R., K. E. Sheridan, D. Ceradini, S. Choe, and N. R. Landau. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.[Abstract/Free Full Text]
    9. 9
  9. Doms, R. W., and J. P. Moore. 2000. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151:F9-F14.
    10. 10
  10. Dragic, T., V. Litwin, G. P. Allaway, S. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.[CrossRef][Medline]
    11. 11
  11. Frank, I., M. J. Piatak, H. Stoessel, N. Romani, D. Bonnyay, J. D. Lifson, and M. Pope. 2002. Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs. J. Virol. 76:2936-2951.[Abstract/Free Full Text]
    12. 12
  12. Frank, I., and M. Pope. 2002. The enigma of dendritic cell-immunodeficiency virus interplay. Curr. Mol. Med. 2:229-248.[CrossRef][Medline]
    13. 13
  13. Frankel, S. S., R. M. Steinman, N. L. Michael, S. R. Kim, N. Bhardwaj, M. Pope, M. K. Louder, P. K. Ehrenberg, P. W. Parren, D. R. Burton, H. Katinger, T. C. VanCott, M. L. Robb, D. L. Birx, and J. R. Mascola. 1998. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J. Virol. 72:9788-9794.[Abstract/Free Full Text]
    14. 14
  14. Granelli-Piperno, A., E. Delgado, V. Finkel, W. Paxton, and R. M. Steinman. 1998. Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J. Virol. 72:2733-2737.[Abstract/Free Full Text]
    15. 15
  15. Heath, S. L., J. G. Tew, A. K. Szakal, and G. F. Burton. 1995. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377:740-744.[CrossRef][Medline]
    16. 16
  16. Hu, J., M. B. Gardner, and C. J. Miller. 2000. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74:6087-6095.[Abstract/Free Full Text]
    17. 17
  17. Ignatius, R., R. M. Steinman, A. Granelli-Piperno, D. Messmer, C. Stahl-Hennig, K. Tenner-Racz, I. Frank, L. Zhong, S. Schlesinger Frankel, and M. Pope. 2001. Dendritic cells during infection with HIV-1 and SIV, p. 487-504. In M. T. Lotze and A. W. Thomson (ed.), Dendritic cells: biology and clinical applications. Academic Press, New York, N.Y.
    18. 18
  18. Jacobson, J. M., I. Lowy, C. V. Fletcher, T. J. O'Neill, D. N. H. Tran, T. J. Ketas, A. Trkola, M. E. Klotman, P. J. Maddon, W. C. Olson, and R. J. Israel. 2000. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182:326-329.[CrossRef][Medline]
    19. 19
  19. Johnson, D. C., and M. T. Huber. 2002. Directed egress of animal viruses promotes cell-to-cell spread. J. Virol. 76:1-8.[Free Full Text]
    20. 19
  20. Ketas, T., P.-J. Klasse, C. Spenlehauer, M. Nessin, I. Frank, M. Pope, J. M. Strizki, G. R. Reyes, B. M. Baroudy, and J. P. Moore. Antagonism of HIV-1 replication by the entry inhibitors SCH-C, RANTES in multiple cell types. AIDS Res. Hum. Retrovir., in press.
    21. 20
  21. Kwon, D. S., G. Gregorio, N. Bitton, W. A. Hendrickson, and D. R. Littman. 2002. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 16:135-144.[CrossRef][Medline]
    22. 21
  22. LaBranche, C. C., G. Galasso, J. P. Moore, D. P. Bolognesi, M. S. Hirsch, and S. M. Hammer. 2001. HIV fusion and its inhibition. Antivir. Res. 50:95-115.[CrossRef][Medline]
    23. 22
  23. Meng, G., X. Wei, X. Wu, M. T. Sellers, J. M. Decker, Z. Moldoveanu, J. M. Orenstein, M. F. Graham, J. C. Kappes, J. Mestecky, G. M. Shaw, and P. D. Smith. 2002. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat. Med. 8:150-156.[CrossRef][Medline]
    24. 23
  24. Mo, H., S. Monard, H. Pollack, J. Ip, G. Rochford, L. Wu, J. Hoxie, W. Borkowsky, D. D. Ho, and J. P. Moore. 1998. Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res. Hum. Retrovir. 14:607-617.[Medline]
    25. 24
  25. Nagashima, K. A., D. A. D. Thompson, S. I. Rosenfield, P. J. Maddon, T. Dragic, and W. C. Olson. 2001. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. 183:1121-1125.[CrossRef][Medline]
    26. 25
  26. O'Brien, W. A., Y. Koyanagi, A. Namazie, J. Q. Zhao, A. Diagne, K. Idler, J. A. Zack, and I. S. Chen. 1990. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 348:69-73.[CrossRef][Medline]
    27. 26
  27. O'Hara, B. M., and W. C. Olson. 2002. HIV entry inhibitors in clinical development. Curr. Opin. Pharmacol. 2:523-528.[CrossRef][Medline]
    28. 27
  28. Olson, W. C., G. E. Rabut, K. A. Nagashima, D. N. Tran, D. J. Anselma, S. P. Monard, J. P. Segal, D. A. Thompson, F. Kajumo, Y. Guo, J. P. Moore, P. J. Maddon, and T. Dragic. 1999. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73:4145-4155.[Abstract/Free Full Text]
    29. 28
  29. Oravecz, T., M. Pall, and M. A. Norcross. 1996. Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step. J. Immunol. 157:1329-1332.[Abstract]
    30. 29
  30. Oravecz, T., M. Pall, J. Wang, G. Roderiquez, M. Ditto, and M. A. Norcross. 1997. Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans. J. Immunol. 159:4587-4592.[Abstract]
    31. 30
  31. Schmidtmayerova, H., B. Sherry, and M. Bukrinsky. 1996. Chemokines and HIV replication. Nature 382:767.[CrossRef][Medline]
    32. 31
  32. Shearer, W. T., R. J. Israel, S. Starr, C. V. Fletcher, D. Wara, M. Rathore, J. Church, J. DeVille, T. Fenton, B. Graham, P. Samson, S. Staprans, J. McNamara, J. Moye, P. J. Maddon, W. C. Olson, et al. 2000. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase I/II study. J. Infect. Dis. 182:1774-1779.[CrossRef][Medline]
    33. 32
  33. Simmons, G., P. R. Clapham, L. Picard, R. E. Offord, M. Rosenkilde, T. W. Schwartz, R. Buser, T. N. Wells, and A. E. Proudfoot. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279.[Abstract/Free Full Text]
    34. 33
  34. Smith, P. D., G. Meng, M. T. Sellers, T. S. Rogers, and G. M. Shaw. 2000. Biological parameters of HIV-1 infection in primary intestinal lymphocytes and macrophages. J. Leukoc. Biol. 68:360-365.[Abstract/Free Full Text]
    35. 34
  35. Spenlehauer, C., A. Kirn, A. M. Aubertin, and C. Moog. 2001. Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. J. Virol. 75:2235-2245.[Abstract/Free Full Text]
    36. 35
  36. Spira, A. I., P. A. Marx, B. K. Patterson, J. Mahoney, R. A. Koup, S. M. Wolinsky, and D. D. Ho. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183:215-225.[Abstract/Free Full Text]
    37. 36
  37. Trkola, A., T. Ketas, V. N. KewalRamani, F. Endorf, J. M. Binley, H. Katinger, J. Robinson, D. R. Littman, and J. P. Moore. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1876-1885.[Abstract/Free Full Text]
    38. 37
  38. Trkola, A., T. J. Ketas, K. A. Nagashima, L. Zhao, T. Cilliers, L. Morris, J. P. Moore, P. J. Maddon, and W. C. Olson. 2001. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75:579-588.[Abstract/Free Full Text]
    39. 38
  39. Trkola, A., W. A. Paxton, S. P. Monard, J. A. Hoxie, M. A. Siani, D. A. Thompson, L. Wu, C. R. Mackay, R. Horuk, and J. P. Moore. 1998. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J. Virol. 72:396-404.[Abstract/Free Full Text]
    40. 39
  40. Trkola, A., A. P. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas, D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG2. J. Virol. 69:6609-6617.[Abstract]
    41. 40
  41. Wesselingh, S. L., and K. A. Thompson. 2001. Immunopathogenesis of HIV-associated dementia. Curr. Opin. Neurol. 14:375-379.[CrossRef][Medline]

Journal of Virology, February 2003, p. 2762-2767, Vol. 77, No. 4
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.4.2762-2767.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Frank, I., Stossel, H., Gettie, A., Turville, S. G., Bess, J. W. Jr., Lifson, J. D., Sivin, I., Romani, N., Robbiani, M. (2008). A Fusion Inhibitor Prevents Spread of Immunodeficiency Viruses, but Not Activation of Virus-Specific T Cells, by Dendritic Cells. J. Virol. 82: 5329-5339 [Abstract] [Full Text]  
  • Teleshova, N., Chang, T., Profy, A., Klotman, M. E. (2008). Inhibitory Effect of PRO 2000, a Candidate Microbicide, on Dendritic Cell-Mediated Human Immunodeficiency Virus Transfer. Antimicrob. Agents Chemother. 52: 1751-1758 [Abstract] [Full Text]  
  • Aquaro, S., Svicher, V., Schols, D., Pollicita, M., Antinori, A., Balzarini, J., Perno, C. F. (2006). Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J. Leukoc. Biol. 80: 1103-1110 [Abstract] [Full Text]  
  • Rao, S., Hu, S., McHugh, L., Lueders, K., Henry, K., Zhao, Q., Fekete, R. A., Kar, S., Adhya, S., Hamer, D. H. (2005). From the Cover: Toward a live microbial microbicide for HIV: Commensal bacteria secreting an HIV fusion inhibitor peptide. Proc. Natl. Acad. Sci. USA 102: 11993-11998 [Abstract] [Full Text]  
  • Ganesh, L., Leung, K., Lore, K., Levin, R., Panet, A., Schwartz, O., Koup, R. A., Nabel, G. J. (2004). Infection of Specific Dendritic Cells by CCR5-Tropic Human Immunodeficiency Virus Type 1 Promotes Cell-Mediated Transmission of Virus Resistant to Broadly Neutralizing Antibodies. J. Virol. 78: 11980-11987 [Abstract] [Full Text]  
  • Fondere, J.-M., Petitjean, G., Huguet, M.-F., Salhi, S. L., Baillat, V., Macura-Biegum, A., Becquart, P., Reynes, J., Vendrell, J.-P. (2004). Human Immunodeficiency Virus Type 1 (HIV-1) Antigen Secretion by Latently Infected Resting CD4+ T Lymphocytes from HIV-1-Infected Individuals. J. Virol. 78: 10536-10542 [Abstract] [Full Text]  
  • Heil, M. L., Decker, J. M., Sfakianos, J. N., Shaw, G. M., Hunter, E., Derdeyn, C. A. (2004). Determinants of Human Immunodeficiency Virus Type 1 Baseline Susceptibility to the Fusion Inhibitors Enfuvirtide and T-649 Reside outside the Peptide Interaction Site. J. Virol. 78: 7582-7589 [Abstract] [Full Text]  
  • Turville, S. G., Santos, J. J., Frank, I., Cameron, P. U., Wilkinson, J., Miranda-Saksena, M., Dable, J., Stossel, H., Romani, N., Piatak, M. Jr, Lifson, J. D., Pope, M., Cunningham, A. L. (2004). Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 103: 2170-2179 [Abstract] [Full Text]  
  • Jacobson, J. M., Israel, R. J., Lowy, I., Ostrow, N. A., Vassilatos, L. S., Barish, M., Tran, D. N. H., Sullivan, B. M., Ketas, T. J., O'Neill, T. J., Nagashima, K. A., Huang, W., Petropoulos, C. J., Moore, J. P., Maddon, P. J., Olson, W. C. (2004). Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542. Antimicrob. Agents Chemother. 48: 423-429 [Abstract] [Full Text]  
  • Teleshova, N., Frank, I., Pope, M. (2003). Immunodeficiency virus exploitation of dendritic cells in the early steps of infection. J. Leukoc. Biol. 74: 683-690 [Abstract] [Full Text]  
  • Vermeire, K., Schols, D. (2003). Specific CD4 down-modulating compounds with potent anti-HIV activity. J. Leukoc. Biol. 74: 667-675 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ketas, T. J.
Right arrow Articles by Pope, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ketas, T. J.
Right arrow Articles by Pope, M.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»